论文部分内容阅读
目的观察咪唑立宾(MZR)对儿童频复发型原发肾病综合征的疗效。方法将2013年4月至2015年1月中南大学湘雅二医院儿童医学中心儿童肾脏专科的住院或门诊登记完整的儿童频复发型原发肾病综合征45例纳入研究,观察对照组(雷公藤+泼尼松)24例和治疗组(咪唑立宾+泼尼松)21例1年内患儿复发次数、波尼松用量、肾小球滤过率、血清白蛋白、尿蛋白、尿酸等指标的变化。结果予以MZR治疗后,治疗组患儿复发次数减少,泼尼松有效用量下降、肾小球滤过率无下降、血清白蛋白水平上升、尿蛋白减少、尿酸水平无明显变化。结论 MRZ是治疗儿童频复发型原发肾病综合征的有效药物。
Objective To observe the efficacy of mizoribine (MZR) in children with recurrent primary nephrotic syndrome. Methods From April 2013 to January 2015, 45 children with frequent primary recurrent nephrotic syndrome who were enrolled in the hospital or outpatient department of pediatric nephrology, Children’s Medical Center, Second Xiangya Hospital of Central South University were included in the study. + Prednisone) and the treatment group (mizoribine + prednisone) in 21 cases within one year of the number of children relapsed, the amount of prednisone, glomerular filtration rate, serum albumin, urine protein, uric acid and other indicators The change. Results After treatment with MZR, the number of relapse, the effective dose of prednisone, the glomerular filtration rate, the level of serum albumin, the decrease of urinary protein and the level of uric acid did not change in treatment group. Conclusion MRZ is an effective drug for the treatment of recurrent primary nephrotic syndrome in children.